A large body of studies has suggested that peroxisome proliferator-activated receptor ; (PPAR;) ligands, such as thiazolidinedione, are potent candidates for chemopreventive agents. MCC-555 is a PPAR;/A dual agonist and has been shown previously to induce apoptosis in vitro; however, the molecular mechanisms by which MCC-555 affects antitumorigenesis in vivo are poorly understood. In this study, we explored the antitumorigenic effects of MCC-555 both in cell culture and in Apc-deficient mice, an animal model for human familial adenomatous polyposis. MCC-555 increased MUC2 expression in colorectal and lung cancer cells, and treatment with the PPAR; antagonist GW9662 revealed that MUC2 induction by MCC-555 was mediated in a PPAR;-dependent manner. Moreover, MCC-555 increased transcriptional activity of human and mouse MUC2 promoters. Subsequently, treatment with MCC-555 (30 mg/kg/d) for 4 weeks reduced the number of small intestinal polyps to 54.8% of that in control mice. In agreement with in vitro studies, enhanced Muc2 expression was observed in the small intestinal tumors of Min mice treated with MCC-555, suggesting that MUC2 expression may be associated at least in part with the antitumorigenic action of MCC-555. In addition, highly phosphorylated extracellular signalregulated kinase (ERK) was found in the intestinal tumors of MCC-555-treated Min mice, and inhibition of the ERK pathway by a specific inhibitor markedly suppressed MCC-555-induced Muc2 expression in vitro. Overall, these results indicate that MCC-555 has a potent tumor suppressor activity in intestinal tumorigenesis, likely involving MUC2 up-regulation by ERK and PPAR; pathways. [Mol Cancer Ther 2008;7(9):2779 -87] 
Introduction
Thiazolidinediones, synthetic peroxisome proliferatoractivated receptor g (PPARg) ligands, are a novel class of antidiabetic drugs for patients with type 2 diabetes, and two of these, rosiglitazone and pioglitazone, are currently available for clinical use (1) . In addition, thiazolidinediones have recently been found to have antitumorigenic activity in a wide variety of cancer cells. As a transcription factor, PPARg targets genes associated with the cell cycle, differentiation, and apoptosis (2) , implying that PPARg ligands can be potent candidates for cancer prevention and/ or therapy. Some of the most extensive studies have been done in the colon, where PPARg is highly expressed in both adenocarcinomas and normal colonic mucosa (3, 4) . For example, PPARg ligands alter the expression of apoptotic and cell proliferation genes, thereby enhancing their antitumorigenic activity through a PPARg-dependent mechanism in colorectal cancer cells (2, 5) . Somatic PPARg mutations were also found in sporadic colon cancers, and these mutations cause deletion of the entire ligand-binding domain and loss of transactivation ability, resulting in incomplete function of the protein (6) . In addition, several reports showed new PPARg-dependent and PPARgindependent target genes of thiazolidinediones, resulting in modulation of cell proliferation and apoptosis in cancer cells (7 -11) . For example, the thiazolidinedione troglitazone was found not only to induce cell death in colon cancer cells (12, 13) but also to reduce the clonogenic capacity of all human colorectal cancer cells tested (3) . Subsequently, the cDNA microarray analysis from colon cancer cells treated by PPARg agonists identified many target genes linked to the cell growth regulatory pathway (14, 15) .
Several animal models for human colorectal cancer have been used to study whether thiazolidinediones possess these antitumorigenic activities in vivo. APC mutations, occurring early in the transformation process, are found in the majority of sporadic colorectal tumors as well as in familial adenomatous polyposis. Several promising chemopreventive agents, such as nonsteroidal anti-inflammatory drugs, have been reported to strongly suppress tumor formation or growth in the small intestine of Min mice (16, 17) . In fact, treatment of Apc 1309 mice with pioglitazone (100 and 200 ppm) for 6 weeks significantly reduced the total number of intestinal polyps to 67% of control (18) .
Results from another animal model, using the colonic carcinogen azoxymethane, support the antitumorigenic activity of troglitazone and pioglitazone with significant suppression of azoxymethane-induced aberrant crypt foci (precursor lesions for colon carcinoma) formation (19) . Although most studies indicate that thiazolidinediones suppress tumors in animal models, troglitazone has also been reported to enhance polyp formation in the intestinal track of Min mice (20) . In addition, it has been recently revealed that troglitazone is hepatotoxic (21) . This variety of actions of thiazolidinedione might be due to a multitarget property of PPARg ligands that remains to be elucidated. Therefore, better thiazolidinedione compounds are needed to achieve antitumorigenic activity with less liver toxicity.
Mucus in the gastrointestinal tract plays an important role as a physiologic barrier between the intestinal contents and underlying epithelial cells. Alteration of the expression of mucins, the major glycoprotein constituents in mucus, is a common feature of colonic neoplasia (22) . Mucin 2 (MUC2), secreted by goblet cells of the small and large intestines, is the major structural component of the mucus gel. Levels of MUC2 mRNA expression are often decreased in colon cancer, although that expression depends on the type of colon cancer and its progression (23 -25) . Furthermore, Muc2 -deficient mice developed adenomas in the small intestine, along with increased proliferation, decreased apoptosis, and increased migration of intestinal adenocarcinoma cells, suggesting MUC2 is linked to suppression of colorectal cancer (26) .
In this study, the novel synthetic PPAR ligand MCC-555 was investigated to determine the effect on MUC2 expression in vitro and in vivo. MCC-555, a novel thiazolidinedione (also known as netoglitazone), was found to have a great effect on decreasing blood glucose levels in animal models of type 2 diabetes and to possess characteristic binding to PPARs (27) . We reported previously that MCC-555 induces apoptosis in human colorectal cancer cells (28) . In this study, we showed that MCC-555 increased MUC2 expression and suppressed intestinal polyposis in Min mice. In addition, we showed a possible mechanism of MUC2 up-regulation via the extracellular signal-regulated kinase (ERK) pathway. This is the first report suggesting that MUC2 is a novel PPARg target gene and that its expression plays a role in colorectal tumorigenesis.
Materials and Methods

Cell Lines and Reagents
Human colorectal cancer SW480 cells, mouse rectal cancer CMT-93 cells, and human lung cancer NCI-H292 cells were purchased from The American Type Culture Collection. MCC-555 (Fig. 1A) was obtained from Mitsubishi Pharma. Ciglitazone, rosiglitazone, prostaglandin 
15-deoxy-D
12,14 -prostaglandin J 2 , and GW9662 were purchased from Cayman Chemical. Troglitazone was obtained from Calbiochem. Anti-MUC2 and anti-actin antibodies were purchased from Santa Cruz Biotechnology, whereas anti-phospho-ERK1/2 (Thr 202 /Tyr 204 ) and anti-ERK1/2 mitogen-activated protein kinases were obtained from Cell Signaling Technology.
RNA Purification and Reverse Transcription-PCR Normal and tumor tissues isolated from the small and large intestine and liver tissues were kept in RNAlater solution (Ambion) and stored at À80jC. Cells were treated with different PPARg ligands at the indicated doses and time points. Total RNA was extracted from these tissues and cells using Perfect RNA Eukaryotic Mini (Eppendorf) or TRIzol (Invitrogen), and cDNA was synthesized from 1 Ag total RNA using an iScript cDNA Synthesis Kit (BioRad) according to the manufacturer's protocol. PCR was done with specific primers: MUC2 (sense 5 ¶-GACCTCCAG-CACAGTTTTATCAACA-3 ¶ and antisense 5 ¶-GCCAGCAA-CAATTGACACGTATCT-3 ¶), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sense 5 ¶-GACCACAGTCCATGC-CATCACT-3 ¶ and antisense 5 ¶-TCCACCACCCTGTTGCTG-TAG-3 ¶), Luciferase Assay Transient transfections were done using the Lipofect-AMINE or LipofectAMINE 2000 transfection reagents (Invitrogen) according to the manufacturer's instructions. The cells were plated in 12-well plates at the concentration of 2 Â 10 5 per well. After overnight growth, human SW480 and NCI-H292 cells were transfected with reporter plasmid containing human MUC2 promoter (phMUC2-2096/ +27LUC) using LipofectAMINE 2000, and mouse CMT-93 cells were transfected with plasmid containing mouse Muc2 promoter (pmMuc2-1001/+29LUC) using Lipofect-AMINE as described previously (29, 30) . After 24 h transfection, the cells were treated with vehicle or MCC-555 for 24 h, and luciferase activity was measured as described previously (31) .
Immunohistochemistry
Small intestine and colon tissues were formalin-fixed, embedded in paraffin, and sectioned at 4 Am thickness. Tissue sections were then heated, deparaffinized in xylene, rehydrated in graded alcohol to PBS, and pretreated with 10 mmol/L citrate buffer (pH 6.0) for 10 min at just below boiling. Endogenous peroxidase activity was quenched by incubation in 3% H 2 O 2 in PBS for 15 min at room temperature, and tissues were incubated with protein block (Biogenex USA) for 30 min at room temperature. Slides were then incubated for 1 h with anti-MUC2 antibody (1:200) followed by biotinylated anti-rabbit IgG (30 min at room temperature) and streptavidin/biotinhorseradish peroxidase complex (20 min at room temperature), which was visualized by 3,3 ¶-diaminobenzidine tetrahydrochloride (0.7 g/L; Biogenex) for 10 min. Slides were lightly counterstained with Mayer's hematoxylin.
Animals and Experimental Design
All animal research procedures were approved by the University of Tennessee Animal Care and Use Committee and were in accordance with NIH guidelines. C57BL/6J Apc Min/+ mice (The Jackson Laboratory) were randomly assigned to their respective experimental groups (n = 7 per each group). Min mice were maintained at 22 F 2jC on a 12 h light/dark cycle and with free access to standard rodent chow and water. MCC-555 was suspended in 1.5% carboxymethylcellulose with 0.2% Tween 20. At age 10 weeks, the experimental group (3 males and 4 females) received the MCC-555 suspension (30 mg/kg/d, 5 days/wk) for 4 weeks by gavage. The control group (4 males and 3 females) was gavaged with the suspending vehicle solution alone. Twenty-four hours after final treatment, the mice were euthanized, and the intestinal tract was isolated and washed with PBS. Tumor numbers and sizes in the small intestine and colon were assessed with a stereoscopic microscope as described previously (32) .
Statistical Analysis Statistical analyses were done with the Mann-Whitney's U test or Student's t test. Results were considered statistically significant at P < 0.05.
Results Enhanced MUC2 mRNA Expression by PPAR; Ligands in Colorectal Cancer Cells
We and others have reported that PPARg ligands display antitumorigenic activity in colorectal cancer (7, 28, 33) , and MUC2 is known to have a tumor suppressor function in colorectal cancer (26) . Hence, we examined whether PPARg ligands increase MUC2 expression in SW480 human colorectal cancer cells. As shown in Fig. 1B , all the tested PPARg ligands increased MUC2 expression 2-to 3-fold. On further examination of MCC-555, we found that MUC2 was increased in a dose-dependent manner (Fig. 1C) . In addition, in CMT-93 mouse colorectal cancer cells, MCC-555 increased Muc2 expression in a dose-dependent manner (Fig. 1D) . Because MUC2 and PPARg ligands play an important role in lung tumorigenesis (34, 35) , human lung cancer cells NCI-H292 were treated with different PPARg ligands, and MUC2 expression was measured. As shown in Fig. 2 , MCC-555 and troglitazone also increased MUC2 expression in lung cancer cells in a dose-dependent manner.
MUC2 Expression Is Mediated in a PPAR;-Dependent Manner Because PPARg ligands can alter target gene expression in both PPARg-dependent and PPARg-independent manners (7, 11, 36) , we examined whether PPARg activation is responsible for MUC2 induction. As we reported previously, 5 Amol/L of the PPARg antagonist GW9662 substantially inhibited PPARg transactivation by MCC-555 (28) . SW480 cells were treated with GW9662 and/or PPARg ligands, and MUC2 expression was measured. As shown in Fig. 3A , pretreatment with GW9662 completely blocked induction of MUC2 expression by MCC-555 and troglitazone in SW480 cells, suggesting that MUC2 induction is probably mediated through a PPARg-dependent pathway. Because MUC2 was increased in human and mouse cell lines in the presence of MCC-555, and PPARg mediates its expression, we examined the transcriptional regulation of MUC2 by MCC-555. The reporter constructs containing human MUC2 promoter (phMUC2-2096/ +27LUC) and mouse Muc2 promoter (pmMuc2-1001/ +29LUC) were transfected into SW480, NCI-H292, and CMT-93 cells. After MCC-555 treatment for 24 h, luciferase activity was measured. As shown in Fig. 3B and C, MCC-555-treated samples showed increased luciferase activity, compared with vehicle-treated samples, indicating that MCC-555 increases MUC2 expression at the transcriptional level.
Suppression of Intestinal Polyp Formation by MCC-555
Because antitumorigenic effects of MCC-555 on intestinal cancer had not been determined previously, we treated Min mice with MCC-555 (30 mg/kg/d) for 4 weeks and evaluated tumor formation in the small intestine and colon. MCC-555 reduced the total numbers of small intestinal polyps to 54.8% of those in control mice (control 125.1 F 22.6 versus MCC-555 68.6 F 9.0). The size distribution of intestinal polyps in control and MCC-555-treated groups is shown in Fig. 4A . Significant reductions of polyp numbers by MCC-555 were observed in polyps measuring 1.0 to 1.5 and 1.5 to 2.0 mm in diameter. Tumor load analysis (polyp number Â polyp size) shows that MCC-555 significantly suppressed intestinal polyp formation (Fig. 4B) . We also examined polyps in the colon and found no statistical significance in polyp number (control 2.3 F 0.6 versus MCC-555 1.4 F 0.5). Because MCC-555 dramatically reduced the number of small intestinal polyps in Min mice and induced MUC2 expression in human and mouse cancer cells (Fig. 1) , the effects of MCC-555 on intestinal Muc2 expression were examined in vivo. The histology of both small and large intestines was typical of Min adenomas, and there was no evidence of deep invasion (Fig. 4C) . To examine the distribution of Muc2, immunostaining was done using small intestine and colonic tissues from Min mice containing tumors. As shown in Fig. 4C , Muc2 was positively stained in goblet cells in the small intestine and colon as reported previously (26) . Interestingly, Muc2 was highly expressed in normal tissue compared with adjacent tumor tissue, supporting the previous report that MUC2 is a tumor suppressor protein.
Increased Muc2 Expression in MCC-555-Treated Min Mice
To investigate whether MCC-555 increases known PPARg (Glut2, aP2, and Lpl) and/or PPARa target genes (l-Fabp and Cyp4a10; refs. 37 -39), the expression of Glut2, l-Fabp, aP2, Cyp4a10, or Lpl in liver tissue was examined by reverse transcription-PCR (RT-PCR). Treatment with MCC-555 increased Glut2 and Cyp4a10 mRNA expression, whereas it did not increase other PPAR target genes, l-Fabp, Lpl, and aP2 (Fig. 5A) . The RT-PCR analysis showed that the level of Muc2 expression in the normal intestine was higher than that in the corresponding tumor tissue from control mice (mouse numbers 6, 7, and 5 in Fig. 5B) , consistent with the Muc2 immunohistochemical staining shown in Fig. 4C . Furthermore, Muc2 mRNA expression was significantly enhanced in MCC-555-treated mouse tumors compared with tumors from control mice (mouse numbers 11-14 in Fig. 5B ). These results indicate that MUC2 expression induced by MCC-555 may play an important role in the tumors of intestinal tract. 
Contribution of the ERK Pathway to MCC-555-Induced MUC2 Expression In vivo and In vitro
It has been shown that MUC2 is regulated by mitogenactivated protein kinase pathways involving ERK1/2 (40), and we have reported that PPARg ligands cause phosphorylation of ERK1/2 in human colorectal cancer cells (7, 28) . To elucidate the molecular mechanism by which MCC-555 increases MUC2 expression, we examined the phosphorylation status of ERK1/2 in the small intestine and colon polyps. Enhanced phosphorylation of ERK1/2 was observed in intestinal tumors of Min mice treated with MCC-555. On the other hand, expression of total ERK1/2 was not affected by MCC-555 treatment (Fig. 6A) . To confirm the role of the ERK1/2 pathway in the regulation of MUC2 expression, SW480 human colorectal cancer cells were pretreated with ERK pathway inhibitors, PD98059 and U0126. As shown in Fig. 6B , U0126 completely inhibited MUC2 induction by MCC-555 in SW480 cells. Another ERK pathway inhibitor, PD98059, also markedly reduced it. Taken together with in vivo and in vitro data, these results show that MCC-555 increases ERK phosphorylation in vivo and in vitro, thereby enhancing MUC2 expression.
Discussion
Promising agents for cancer prevention have been shown to consistently suppress tumorigenesis or the rate of tumor growth in Min mice, which served as a model for familial adenomatous polyposis. Our results showed that treatment of Min mice with MCC-555 significantly suppressed polyp formation in the small intestine and slightly decreased colonic tumorigenesis (Fig. 4) . Although a growing body of evidence from in vitro studies suggests that thiazolidinediones have an antiproliferative effect (41) and induce apoptosis (7, 12, 28) and differentiation (3, 5) in colorectal cancer cells, conflicting studies showing that these agents can either increase or reduce colonic tumors in mice, raising concerns about the role of PPARg in colon cancer. These inconsistent results from in vivo studies might be explained by the dose of PPARg ligand used and/or properties of the various PPARs. For instance, it has been reported that PPARg ligands show either tumor-suppressing or tumorpromoting actions in breast cancer cells depending on the doses used (42) . Moreover, Niho et al. showed that both PPARg and PPARa ligands, pioglitazone and bezafibrate, respectively, suppress polyp formation in Apc 1309 mice (18) . Indeed, pioglitazone is also a weak PPARa agonist (43) . We have reported that MCC-555 showed higher PPARa transactivation activity than any other synthetic PPARg ligand (9-fold versus troglitazone, 7-fold versus ciglitazone, and 5-fold versus rosiglitazone), although PPARg activation by MCC-555 was less than that produced by troglitazone, rosiglitazone, and ciglitazone (28) . In this study, we also found that MCC-555 increased not only a PPARg target gene but also a PPARa target gene. This evidence strongly suggests that MCC-555 is a dual agonist for PPARg and PPARa. The dual agonist function should be considered to be involved in the antitumorigenic activity of MCC-555 and other PPARg ligands.
Min mice were treated with MCC-555 at a dose of 30 mg/ kg, a dose used in previous studies (44) . This dose could increase PPARg-responsive genes in adipose tissue of mice and also could suppress growth of prostate cancer xenografts without lowering body weight in nude mice (44) . In this study, treatment with MCC-555 increased both construct were treated with 10 Amol/L MCC-555 for 24 h, and luciferase activity was measured as described in Materials and Methods. Y axis, fold increase of relative luciferase unit (RLU) compared with relative luciferase unit of vehicle-treated samples. Mean F SD from three replicates. *, P < 0.05; **, P < 0.01, from vehicle-treated samples.
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Mol Cancer Ther 2008;7 (9 PPARg-and PPARa-responsive genes including Glut2 and Cyp4a10, respectively, supporting a dual agonist. On the other hand, MCC-555 failed to induce PPAR-target genes l-Fabp and aP2 in liver tissue (Fig. 5A) . A recent study suggested that ectopic induction of aP2 by PPAR activation is tissue specific in the mouse (39) . Thus, expression of aP2 in the small intestine was investigated; however, the expression was not affected by MCC-555 treatment (data not shown). We also analyzed expression of Lpl in the liver because treatment with pioglitazone could increase its expression in Min mice (18) . However, MCC-555 did not affect Lpl expression in the liver. Because MCC-555 has a weak PPARg binding affinity and transactivation, compared with other PPARg ligands (27, 28) , the concentration of MCC-555 used may not be enough to induce all PPARgresponsive genes.
In this study, we found that the tumor suppressor MUC2 is commonly induced by PPARg ligands in several human cancer cells (Figs. 1 and 2 ). Muc2 was also found to be consistently up-regulated in intestinal tumors of Min mice following MCC-555 treatment. Because all tested PPARg ligands increased MUC2 expression in SW480 cells, they likely work via a PPARg-dependent pathway. Indeed, usage of GW9662, a PPARg inhibitor, showed that MUC2 expression occurs in a PPARg-dependent manner (Fig. 3A) . Interestingly, PPARg ligands did not induce MUC2 expression in other colorectal cancer cells such as HT-29 and Caco-2 (data not shown). Recently, it was shown that MUC2 expression in HT-29 and Caco-2 cells was repressed epigenetically by DNA methylation and repressive histone code (45) . This may explain why we were unable to induce MUC2 expression by PPARg ligands in these two cell types, although these cells have been shown to express active PPARg (3) .
It has been suggested that alteration in mucin gene expression is likely associated with both the early steps of colon cancer development and later tumor progression. Inactivation of Muc2 causes tumor formation accompanied by reduced apoptosis and increased proliferation and migration of intestinal adenocarcinoma cells (26) . Oncogenic SOX9 or tumor suppressor p53 regulates MUC2 transcriptional activity negatively and positively (46, 47) . These studies on transcriptional regulation of MUC2 imply that MUC2 can be associated with tumor suppression. In agreement with its tumor-suppressing function, MUC2 expression is reduced in tumors compared with the corresponding sections of the small intestine and colon. Our results clearly showed that MCC-555 increased MUC2 expression in human cancer cells and in Min mice. Thus, MUC2 may be, in part, responsible for the antitumorigenic action of MCC-555.
To find the molecular mechanism underlying MUC2 induction by MCC-555, the ERK pathway was analyzed, because MCC-555 promotes phosphorylation of ERK1/2, but not p38 mitogen-activated protein kinase and the c-Jun NH 2 -terminal kinase, in human colorectal cancer cells (28) . It is likely that the ERK signaling pathway is a major determinant in the control of diverse cellular processes, such as cell survival, proliferation, differentiation, and motility. However, the ERK pathway contributes to apoptosis induced by some genotoxic agents, such as diallyl disulfide and L-ascorbic acid (48, 49) . In fact, ERK pathway inhibition by U0126 and PD98059 reduced MUC2 induction by MCC-555, suggesting that the ERK pathway regulates MUC2 expression (Fig. 6) . Recently, Li et al. reported that troglitazone-induced apoptosis is in part ERK1/2 dependent, supporting our observation (50) . In addition to this study, we showed, for the first time, that MCC-555 promotes phosphorylation of ERK1/2 in vivo. These results strongly suggest that activation of the ERK signaling pathway by a synthetic PPARg ligand is linked to tumor suppression. An understanding of the ERK pathway may be thus an important step toward using agents including PPARg ligands for cancer prevention. Although the use of MCC-555 is not striking when compared with results of various nonsteroidal anti-inflammatory drugs or epidermal growth factor receptor inhibitors, our data provide a novel finding that the tumor suppressor MUC2 is a target of PPARg and the possibility of combinational use of MCC-555 with nonsteroidal anti-inflammatory drugs or epidermal growth factor receptor inhibitors in colorectal cancer prevention studies.
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